Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

被引：79

作者：

Gault, VA ^{[1
]}

O'Harte, FPM ^{[1
]}

Flatt, PR ^{[1
]}

机构：

[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland

来源：

NEUROPEPTIDES | 2003年 / 37卷 / 05期

关键词：

D O I：

10.1016/j.npep.2003.09.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucose-dependent insulinotropic polypeptide (GIP or gastric inhibitory polypeptide) is a gastrointestinal hormone, which modulates physiological insulin secretion. Due to its insulinotropic activity, there has been a considerable increase of interest in utilising the hormone as a potential therapy for type 2 diabetes. One of the difficulties in attempting to harness the insulinotropic activity of GIP into an effective therapeutic agent is its short biological half-life in the circulation. However, recent years have witnessed the development of a substantial number of designer enzyme-resistant 'super GIP' molecules with potent insulinotropic and anti-diabetic properties. In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders. The present review aims to highlight the rapidly emerging potential therapeutic applications of GIP, and especially, enzyme-resistant GIP analogues. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：253 / 263

页数：11

共 107 条

[1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[2] Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice [J].

Ahrén, B ;

Holst, JJ ;

Mårtensson, H ;

Balkan, B .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :239-245

[3] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].

Ahrén, B ;

Simonsson, E ;

Larsson, H ;

Landin-Olsson, M ;

Torgeirsson, H ;

Jansson, PA ;

Sandqvist, M ;

Båvenholm, P ;

Efendic, S ;

Eriksson, JW ;

Dickinson, S ;

Holmes, D .

DIABETES CARE, 2002, 25 (05) :869-875

[4] Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells [J].

Almind, K ;

Ambye, L ;

Urhammer, SA ;

Hansen, T ;

Echwald, SM ;

Holst, JJ ;

Gromada, J ;

Thorens, B ;

Pedersen, O .

DIABETOLOGIA, 1998, 41 (10) :1194-1198

[5]

[Anonymous], CAN J PHYSL PHARM

[6] Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants [J].

Baba, ASH ;

Harper, JMM ;

Buttery, PJ .

COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2000, 127 (02) :173-182

[7]

BAILEY CJ, 1982, INT J OBESITY, V6, P11

[8] IMMUNOREACTIVE GASTRIC-INHIBITORY POLYPEPTIDE AND K-CELL HYPERPLASIA IN OBESE HYPERGLYCEMIC (OB/OB) MICE FED HIGH-FAT AND HIGH-CARBOHYDRATE CAFETERIA DIETS [J].

BAILEY, CJ ;

FLATT, PR ;

KWASOWSKI, P ;

POWELL, CJ ;

MARKS, V .

ACTA ENDOCRINOLOGICA, 1986, 112 (02) :224-229

[9]

BAILEY CJ, 2003, TXB DIABETES, V1

[10] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats [J].

Balkan, B ;

Kwasnik, L ;

Miserendino, R ;

Holst, JJ ;

Li, X .

DIABETOLOGIA, 1999, 42 (11) :1324-1331

← 1 2 3 4 5 6 7 8 9 10 →